NO20063320L - Use of gaboxadol for the treatment of insomnia - Google Patents

Use of gaboxadol for the treatment of insomnia

Info

Publication number
NO20063320L
NO20063320L NO20063320A NO20063320A NO20063320L NO 20063320 L NO20063320 L NO 20063320L NO 20063320 A NO20063320 A NO 20063320A NO 20063320 A NO20063320 A NO 20063320A NO 20063320 L NO20063320 L NO 20063320L
Authority
NO
Norway
Prior art keywords
insomnia
treatment
gaboxadol
amount
patient
Prior art date
Application number
NO20063320A
Other languages
Norwegian (no)
Inventor
Bjarke Ebert
Jonas Lundahl
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34684447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20063320(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20063320L publication Critical patent/NO20063320L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den foreliggende oppfirmelse vedrører en fremgangsmåte for å behandle insonmi i en human pasient som trenger det ved å administrere en mengde gaboxadol per dag til pasienten, nevnte mengde er effektiv for behandlingen av insomni.The present invention relates to a method of treating insomnia in a human patient who needs it by administering an amount of gaboxadol per day to the patient, said amount being effective for the treatment of insomnia.

NO20063320A 2003-12-18 2006-07-18 Use of gaboxadol for the treatment of insomnia NO20063320L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200301877 2003-12-18
PCT/DK2004/000861 WO2005058313A1 (en) 2003-12-18 2004-12-14 Use of gaboxadol for treating insomnia

Publications (1)

Publication Number Publication Date
NO20063320L true NO20063320L (en) 2006-07-18

Family

ID=34684447

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063320A NO20063320L (en) 2003-12-18 2006-07-18 Use of gaboxadol for the treatment of insomnia

Country Status (17)

Country Link
EP (1) EP1720547A1 (en)
JP (1) JP2007515415A (en)
KR (1) KR20060103335A (en)
CN (1) CN1893942A (en)
AR (1) AR047154A1 (en)
AU (1) AU2004298313A1 (en)
BR (1) BRPI0415893A (en)
CA (1) CA2550610A1 (en)
EA (1) EA200600989A1 (en)
IL (1) IL176239A0 (en)
IS (1) IS8390A (en)
MX (1) MXPA06006685A (en)
NO (1) NO20063320L (en)
SG (1) SG133601A1 (en)
TW (1) TW200528098A (en)
WO (1) WO2005058313A1 (en)
ZA (1) ZA200602762B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
EP1906953A4 (en) * 2005-04-29 2009-05-20 Lundbeck & Co As H FORMS OF ACID SALTS AND BASIC SALTS OF GABOXADOL
KR20240160666A (en) 2015-07-17 2024-11-11 오비드 테라퓨틱스 인크. Methods of treating developmental disorders with gaboxadol
JP2020533415A (en) * 2017-09-12 2020-11-19 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Use of gaboxador in the treatment of narcolepsy
AU2019345312A1 (en) 2018-09-20 2021-03-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
CN113423399A (en) 2018-12-17 2021-09-21 奥维德医疗公司 Use of gaboxadol for treating non-24hour sleep-wake disorders
WO2021127308A1 (en) 2019-12-18 2021-06-24 Ovid Therapeutics Inc. GABOXADOL FOR THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19525598C2 (en) * 1995-07-13 1997-09-25 Max Planck Gesellschaft sleeping pills
EP1389091A1 (en) * 2001-05-21 2004-02-18 H. Lundbeck A/S Granular preparations of gaboxadol

Also Published As

Publication number Publication date
KR20060103335A (en) 2006-09-28
CN1893942A (en) 2007-01-10
CA2550610A1 (en) 2005-06-30
WO2005058313A1 (en) 2005-06-30
BRPI0415893A (en) 2007-01-09
SG133601A1 (en) 2007-07-30
JP2007515415A (en) 2007-06-14
AU2004298313A1 (en) 2005-06-30
AR047154A1 (en) 2006-01-11
MXPA06006685A (en) 2006-08-23
EA200600989A1 (en) 2006-10-27
EP1720547A1 (en) 2006-11-15
IL176239A0 (en) 2006-10-05
ZA200602762B (en) 2007-06-27
TW200528098A (en) 2005-09-01
IS8390A (en) 2006-03-30

Similar Documents

Publication Publication Date Title
EA200501319A1 (en) METHODS OF TREATMENT OF PATIENTS BY INTRODUCING ANTAGONIST OF NERVES GROWTH FACTOR AND NONSTEROID ANTI-INFLAMMATORY MEANS AND CONTAINING THEIR COMPOSITIONS
EA201301078A1 (en) NEW THERAPEUTIC APPROACHES IN THE TREATMENT OF SMT AND RELATED DISORDERS
BR0308928A (en) Use of botulinum toxin for the treatment of cardiovascular disease, as well as composition for use in a cardiovascular procedure.
NO20074999L (en) Method and preparation for the treatment of peripheral vascular diseases
ATE457166T1 (en) ORAL COMPOSITIONS FOR TREATING DIABETES
NO20050204L (en) Combinations of drugs for the treatment of neoplasms
UA94899C2 (en) Fixed dosing of her antibodies
ATE389411T1 (en) STRONTIUM COMPOUND FOR THE TREATMENT OF SUB-DERMAL SOFT TISSUE PAIN
DK1263729T3 (en) Cyclic aza compounds for use in the treatment of serotonin-related diseases
BRPI0510094A (en) use of flibanserin for premenstrual treatment and other female sexual disorders
NO20083036L (en) Use of benzofused heterocyclic sulfamide derivatives for the treatment of depression
CY1115690T1 (en) ARTHROSPIRA BASED COMPOSITIONS AND THEIR USES
DE122009000036I2 (en) Use of dapoxetine, a selective serotonin uptake inhibitor, for the treatment of sexual dysfunction
DE502005008058D1 (en) Saturated and unsaturated 3-pyridyl-benzocyclo-cyclo-ethyl-amine for the treatment of pain, depression and anxiety
NO20054371L (en) Somatostatin-dopamine chimeric analogs
MX2009003532A (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin.
EA200970436A1 (en) CARBAMATE CONNECTIONS FOR THE TREATMENT OF DEPRESSION
EA200700407A1 (en) HINAZOLIN DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOCYTHEMIA
PT1631275E (en) Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
ATE499933T1 (en) USE OF BETAIN TO TREAT INTERMITTENS CLAUDICATIO
EA200600989A1 (en) APPLICATION OF GABOXADOL FOR THE TREATMENT OF CEREBELLS
EA200501865A1 (en) ANALOGUES OF TIOVOLFRAMATOV AND THEIR APPLICATION
NO20054034L (en) Procedures for the treatment of hypothyroidism.
BR0111900A (en) Use of an angiotensin ii type 1 receptor antagonist, pharmaceutical formulation, and methods for treating a vascular headache condition and for treating migraine
MXPA05013975A (en) Treatment of amyloid- and epileptogenesis-associated diseases.

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104